Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...

In individuals who started antiretroviral therapy during acute HIV infection, the proliferative capacity of HIV-specific CD8+ ...

Opinion: "While the obstacles we face may be significant, Lenacapavir represents a monumental breakthrough in the fight ...

A Northwestern Medicine study published in Nature Communications has revealed how HIV can protect infected cells by altering ...

The US Preventive Services Task Force (USPSTF) is expanding its recommendation for antiretrovirals in HIV now that more options are available on the market. "With these new options we could ...

After four decades of hard-won progress toward curbing the HIV epidemic, the face of the disease is changing.

The first randomized study investigating a NRTI-sparing regimen, based on the association of NNRTI and PI in the case of indinavir and EFV, documented the virologic inferiority of this combination ...

Two antiretroviral suppliers have entered business rescue, raising concerns over availability. More than six million people ...

The Health Department has moved to reassure HIV patients that the country is not at risk of running out of antiretroviral ...